On April 20, 2026, Hong Kong-listed company GR LIFE STYLE (00108.HK) announced a plan to acquire a 78.3% equity stake in the internet healthcare platform Chunyu Doctor for a total consideration of 269 million yuan. The transaction is structured with 20% cash and 80% stock payment. The shares issued as part of the consideration are priced at HK$1.6 per share, representing a 59.8% discount to the closing price on the agreement signing date. However, controversy surrounding this acquisition remains unresolved: the target company's revenue has halved over three years, it continues to report losses, its valuation has shrunk by over 95%, and the acquirer itself is struggling with persistent losses. More critically, the 269 million yuan acquisition does not include any performance commitment clauses.
The acquisition involves a dual arrangement of a discounted purchase and a VIE structure. In early December 2025, GR LIFE STYLE formally announced, through its operating entity Changsha Yurui Health Technology Co., Ltd., the acquisition of a 78.3% stake in Beijing Chunyu Tianxia Software Co., Ltd. (operator of the "Chunyu Doctor" platform) for 269 million yuan, implying an overall valuation for the target of approximately 340 million yuan. This price represents a decline of over 95% compared to Chunyu Doctor's peak valuation of nearly $1 billion.
The payment arrangement is implemented in two stages: the first payment, constituting 20% of the total consideration (approximately 53.8 million yuan), is made in cash; the second payment, constituting 80%, involves issuing 136 million consideration shares to 14 Class A subscribers and paying 17.1 million yuan in cash to 2 Class B subscribers. The issuance price for the consideration shares is HK$1.6 per share, a 59.8% discount to the HK$3.98 closing price on the agreement signing date. Furthermore, as digital healthcare is an industry with foreign ownership restrictions, GR LIFE STYLE achieves control through a VIE structure. This arrangement faces uncertainties due to factors such as the normalization of thorough regulatory reviews and tightening supervision of foreign debt.
The target company faces significant challenges. According to the acquisition announcement, for 2023, 2024, and the first ten months of 2025, the company's revenues were 101 million yuan, 66.226 million yuan, and 51.048 million yuan respectively, showing a year-on-year declining trend. Post-tax losses for the same periods were 9.572 million yuan, 22.949 million yuan, and 2.918 million yuan respectively, accumulating to over 35 million yuan in total losses. As of October 31, 2025, the company's unaudited net assets were only approximately 94.9 million yuan.
Although the platform still boasts a base of 180 million registered users, 690,000 contracted doctors, and 330,000 daily consultations, these assets are increasingly difficult to translate into growth expectations. Under intense pressure from new-generation AI-driven products like Ant Afu (with 30 million monthly active users), Alibaba Health's "Hydrogen Ion," and OpenAI's ChatGPT Health, independent platforms centered on traditional online consultations are facing a severe revaluation of their worth.
The acquirer, GR LIFE STYLE, is also deeply mired in operational pressures. The company's core business focuses primarily on property development and investment, and property management services. In 2024, the company's total revenue was HK$310 million, a year-on-year decrease of 12.1%, with revenues from both core segments showing a declining trend for three consecutive years. Dragged down by a net fair value loss of HK$934.8 million on investment properties, the comprehensive loss for 2024 reached HK$919.3 million. For the full year 2025, although company revenue increased by 5.77% year-on-year to HK$328 million, the annual loss still amounted to HK$110 million. As a "rescuer" that has reported losses for four consecutive years, its ability to integrate the also loss-making Chunyu Doctor is highly questionable.
The most concerning aspect of this transaction is the complete absence of any performance commitments or valuation adjustment mechanisms. Regardless of potential continued losses in 2026, 2027, or beyond, any future losses of the target company will be directly borne by the listed company, with the sellers bearing no compensation responsibility. In contrast, a comparable Hong Kong acquisition around the same time – Gaoke Bridge's acquisition of Futong Optoelectronics – included at least a HK$50 million profit guarantee for the first year. The acquisition of Chunyu Doctor by GR LIFE STYLE lacks even such a "first-year promise." This omission turns the transaction into a one-sided arrangement where the "seller secures their proceeds, and the buyer bears the risk alone."
Following the acquisition, GR LIFE STYLE promptly promoted a strategic cooperation between Chunyu Doctor and home service provider Yuanfang Edelweiss, setting a target of "200 million yuan in revenue for the first year, breaking through 1 billion yuan within three years."
However, achieving this goal faces multiple obstacles. First, Chunyu Doctor's revenue for the first ten months of 2025 was only 51.048 million yuan, leaving a vast gap to the first-year target of 200 million yuan. Second, while the cooperation model essentially involves complementary integration of "online AI healthcare + offline home services," the business synergy between the two parties requires a long磨合周期, and whether it can generate substantial revenue growth in the short term remains unproven. Third, the competitive landscape of the internet healthcare industry has fundamentally changed. Giants like Alibaba Health and JD Health are exerting overwhelming pressure on independent platforms through their ecosystem advantages, while AI-driven industry consolidation is accelerating.
Although GR LIFE STYLE has publicly declared that it has "fully upgraded to an AI-driven healthy quality lifestyle service provider," judging by the design of the transaction structure, management's confidence in this transformation does not seem to have translated into substantive guarantees for investors.
The sale of Chunyu Doctor, following the acquisition of Haodf.com by Ant Group, represents another case of an early-generation internet healthcare platform changing hands at a "discounted price." From preparing for an IPO in 2015 with a peak valuation approaching $1 billion to its current "fire sale" for 340 million yuan, Chunyu Doctor's trajectory of value regression is highly representative. It reflects the core challenge facing the entire industry: under the triple pressures of AI technology reshaping competition, ecosystem giants applying overwhelming force, and a long-term absence of profitability, independent internet healthcare platforms lacking ecosystem support are accelerating their marginalization.
As the industry shifts from "connecting doctors and patients" to being "intelligently driven," user scale and first-mover advantages are no longer sufficient to support valuations. GR LIFE STYLE's acquisition of Chunyu Doctor for 269 million yuan might appear to be a low-price "bargain hunt," but in reality, it bundles the acquirer's own pressured core business with the target's ongoing loss risks.
The transaction structure, devoid of performance commitments, further stamps this acquisition from the outset with the mark of the "seller cashing out and the buyer bearing the brunt." For the minority shareholders of GR LIFE STYLE, the real test has just begun. After the acquisition "story" is told, what remains is the "exam paper" of performance delivery. And on this paper, the first question is: how to transform a loss-making internet healthcare company into a new growth engine for the listed company, without the protection of performance commitments?